Trial Profile
BCMA-CD38 Bispecific Chimeric Antigen Receptor (CAR)-Modified T Cells in the Treatment of Relapsed or Refractory Multiple Myeloma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 11 Dec 2019
Price :
$35
*
At a glance
- Drugs Anti BCMA anti CD38 bispecific chimeric antigen receptor T cell therapy Shengyan Pharmaceutical Technology (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man
- 10 Dec 2019 Results presented at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 07 Sep 2018 New trial record